StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)

Investment analysts at StockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

ObsEva Price Performance

The stock has a market cap of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68. The company’s fifty day moving average is $0.01 and its 200-day moving average is $0.04. ObsEva has a 52 week low of $0.08 and a 52 week high of $2.14.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.